1-20 of 2055
proteasome inhibitors
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

YWHAE/14-3-3ε expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma

Yan Xu, Mariateresa Fulciniti, Mehmet K. Samur, Matthew Ho, Shuhui Deng, Lanting Liu, Kenneth Wen, Tengteng Yu, Zuzana Chyra, Sanika Dereibal, Li Zhang, Yao Yao, Chandraditya Chakraborty, Eugenio Morelli, Na Li, Michael A. Lopez, Tommaso Perini, Shidai Mu, Gang An, Rafael Alonso, Giada Bianchi, Yu-Tzu Tai, Kenneth C. Anderson, Lugui Qiu, Nikhil C. Munshi
Journal: Blood
Blood (2020) 136 (4): 468–479.
https://doi.org/10.1182/blood.2019004147
Published: 2020
Includes: Supplemental data
Journal Articles

AL patients don’t dare go without dara

Clinical Trials & Observations
Angela Dispenzieri
Journal: Blood
Blood (2020) 135 (18): 1509–1510.
https://doi.org/10.1182/blood.2020005436
Published: 2020
Journal Articles

Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017;130(5):597-605.

Journal: Blood
Blood (2020) 135 (13): 1071.
https://doi.org/10.1182/blood.2020005086
Published: 2020
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-6.
https://doi.org/10.1182/blood-2019-132629
Published: 2019
Journal Articles

Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis

Danny Luan, BS, MPH, Koen Van Besien, MD PhD, Paul J Christos, Dr.P.H., M.S., Roger Pearse, MD PhD, Danielle Guarneri, BS, CCRP, Morton Coleman, MD, Ruben Niesvizky, MD, Cara A. Rosenbaum, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4579.
https://doi.org/10.1182/blood-2019-127723
Published: 2019
Journal Articles

Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma

Yan Song, PhD, Ting DU, PhD, Arghya Ray, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4403.
https://doi.org/10.1182/blood-2019-122952
Published: 2019
Journal Articles

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia

Nina D. Wagner-Johnston, MD, Stephen J. Schuster, MD, Sven de Vos, MD PhD, Gilles A. Salles, MD PhD, Wojciech Jurczak, MD PhD, Nishan Rajakumaraswamy, MD, Guan Xing, PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4006.
https://doi.org/10.1182/blood-2019-121936
Published: 2019
Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, MD, David S. Ziegler, MBBS, FRACP, MD, Francisco José Bautista Sirvent, MD PhD, Andishe Attarbaschi, MD, Lia Gore, MD, Franco Locatelli, MD PhD, Maureen M O'Brien, MD, Melinda Pauly, MD, Mihaela Obreja, PhD, Christopher L. Morris, PhDMD, Andre Baruchel, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3873.
https://doi.org/10.1182/blood-2019-127350
Published: 2019
Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4336.
https://doi.org/10.1182/blood-2019-126959
Published: 2019
Journal Articles

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Laura Ann Bruins, BS, Cecilia Bonolo De Campos, PhD, William Stewart, Esteban Braggio, PhD, A Keith Stewart, M.B. Ch.B.
Journal: Blood
Blood (2019) 134 (Supplement_1): 4337.
https://doi.org/10.1182/blood-2019-127149
Published: 2019
Journal Articles

Metaphase Cytogenetics for Risk Stratification in Newly Diagnosed Multiple Myeloma

Patrick Mellors, Moritz Binder, MDMPH, Rhett P. Ketterling, MD, Patricia Griepp, MD, Linda B Baughn, PhD, Francis K. Buadi, MB, CHB, Martha Q. Lacy, MD, Morie A. Gertz, MD, Angela Dispenzieri, MD, Suzanne Haymann, MD, Prashant Kapoor, MD, Wilson I Gonsalves, MD, Yi Lisa Hwa, CNP, DNP, Amie Fonder, PA-C, MS, Miriam A. Hobbs, APRN, CNP, DNP, Taxiarchis Kourelis, MD, Rahma M Warsame, MD, John A. Lust, MD PhD, Nelson Leung, MD, Ronald S. Go, MD, Robert A. Kyle, MD, S. Vincent Rajkumar, MD, Shaji K. Kumar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4396.
https://doi.org/10.1182/blood-2019-122291
Published: 2019
Journal Articles

Targeting Glycolysis in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant in Hypoxic Conditions

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4344.
https://doi.org/10.1182/blood-2019-129818
Published: 2019
Journal Articles

Ixazomib Modulates Bone Remodeling and Actives Sonic Hedgehog Pathways

Daniele Tibullo, PhD, Anna Longo, PhD, Alessandra Romano, MD PhD, Alessandro Barbato, Cesarina Giallongo, PhD, Michelino Di Rosa, PhD, Carmelina Daniela Anfuso, Gabriella Lupo, Concetta Conticello, MD, Nunzio Vicario, PhD, Rosario Gulino, PhD, Rosalba Parenti, PhD, Giuseppe A. Palumbo, MD PhD, Giovanni Li Volti, MD PhD, Francesco Di Raimondo, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4345.
https://doi.org/10.1182/blood-2019-129927
Published: 2019
Journal Articles

Role of High-Dose Melphalan and Autologous Stem Cell Transplantation in Multiple Myeloma Patients Presenting with t(11;14)

Eduardo Sobejano, Veronica Gonzalez De La Calle, MD PhD, Victor Higuero, Fernando Escalante, MD, Ramón García-Sanz, MD PhD, Daniel Presa, Raul Azibeiro, Marta Fonseca, Beatriz Rey, Noemi Puig, MD PhD, Norma C. Gutierrez, MD PhD, Pilar Leóz, Jorge Labrador, Carmen Aguilera, Jose Maria Alonso Alonso, Rosa López, Aránzazu García Mateo, PhD, Alfonso Garcia, Roberto Hernández, Abelardo Barez Garcia, Julio Dávila, Elena Redondo, Victor Quirós, María-Victoria Mateos, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4580.
https://doi.org/10.1182/blood-2019-129880
Published: 2019
Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4404.
https://doi.org/10.1182/blood-2019-121937
Published: 2019
Journal Articles

Germline Variation Predicts Treatment Response in Multiple Myeloma

Kyle Roter, BSc, Donglei Hu, PhD, Alyssa Clay-Gilmour, PhD, Scott Huntsman, Nina D. Shah, MD, Sandy W. Wong, MD, Thomas G. Martin, III, MD, Jeffrey Lee Wolf, MD, Moritz Binder, MDMPH, Shaji K. Kumar, MD, S. Vincent Rajkumar, MD, Susan L. Slager, PhD, Celine M. Vachon, PhD, Elad Ziv, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4397.
https://doi.org/10.1182/blood-2019-129344
Published: 2019
Journal Articles

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Nouf Alrasheed, Lydia Lee, Huw Richards, William Wilson, Oliver C Cohen, MBBS, BSc, FRCPath, Selina J Chavda, Jake Henry, Andrew Furness, Melody Chin, Daria Galas-Filipowicz, Charalampia Kyriakou, Neil K Rabin, Sergio A Quezada, Kwee Yong
Journal: Blood
Blood (2019) 134 (Supplement_1): 4368.
https://doi.org/10.1182/blood-2019-126682
Published: 2019
Journal Articles

Subsequent Treatments, Responses and Survival in the Real World for Patients with Relapsed Multiple Myeloma Following Treatment with Lenalidomide

Jessica B Taube, MBBChir, Catherine SY Lecat, MBBS, Simon Cheesman, BPharm, Gabriel Wallis, Charalampia Kyriakou, Lydia Lee, Shameem Mahmood, Xenofon Papanikolaou, Christopher Parrish, MB BChir MA MRCP FRCPath PhD, Neil K Rabin, Sajitha Sachchithananthan, Jonathan Sive, MD, Ashutosh D. Wechalekar, Kwee Yong, Gordon Cook, Rakesh Popat
Journal: Blood
Blood (2019) 134 (Supplement_1): 4340.
https://doi.org/10.1182/blood-2019-128266
Published: 2019
Journal Articles

Prognostic Significance of FOXO3 in Pediatric Acute Myeloid Leukemia (AML) Patients Treated with Bortezomib Addition to Standard Therapy: Results from a Children's Oncology Group Phase 3 Clinical Trial

Anneke D. van Dijk, BS, Peter P. Ruvolo, PhD, Fieke W Hoff, BSc, Yihua Qiu, Alan S Gamis, MD MPH, Richard Aplenc, MD PhD, Anders E. Kolb, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, Eveline S. de Bont, MD PhD, Sophia W.M. Bruggeman, PhD, Terzah M Horton, MD PhD, Steven M. Kornblau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2676.
https://doi.org/10.1182/blood-2019-128579
Published: 2019
Journal Articles

NRF2 Is Targeted By the Polyphenol Quercetin and Induces Apoptosis, in Part, through up Regulation of Pro Apoptotic Mirs

Marisa Claudia Alvarez De Prax, PhD, Karla P.V Ferro, PhD, Irene Santos, Cristiane Okuda Torello, PhD, Myriam Salazar-Terreros, PhDMSc, Sara T Olalla Saad, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2529.
https://doi.org/10.1182/blood-2019-130982
Published: 2019